Bicara Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Bicara Therapeutics has a total shareholder equity of $192.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $208.8M and $16.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$203.86m |
| Equity | US$192.50m |
| Total liabilities | US$16.28m |
| Total assets | US$208.78m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BCAX's short term assets ($206.1M) exceed its short term liabilities ($16.1M).
Long Term Liabilities: BCAX's short term assets ($206.1M) exceed its long term liabilities ($217.0K).
Debt to Equity History and Analysis
Debt Level: BCAX is debt free.
Reducing Debt: BCAX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCAX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BCAX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 24.1% each year.